StockNews.com Initiates Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)

StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a note issued to investors on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, Maxim Group reaffirmed a “hold” rating on shares of Galmed Pharmaceuticals in a report on Friday, April 4th.

Galmed Pharmaceuticals Price Performance

Shares of GLMD stock opened at $1.33 on Friday. Galmed Pharmaceuticals has a one year low of $1.21 and a one year high of $23.80. The stock has a fifty day moving average price of $1.99 and a 200 day moving average price of $2.83. The stock has a market cap of $2.20 million, a P/E ratio of -0.08 and a beta of 0.70.

Institutional Investors Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC purchased a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned approximately 3.97% of Galmed Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 76.14% of the company’s stock.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.